This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clovis Oncology 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clovis Oncology.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	31.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Clovis Oncology 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

DB:C6O - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2022	133	-252	-176	-176	N/A
6/30/2022	140	-263	-181	-181	N/A
3/31/2022	145	-258	-193	-193	N/A
12/31/2021	149	-265	-196	-196	N/A
9/30/2021	156	-299	-211	-211	N/A
6/30/2021	157	-310	-219	-219	N/A
3/31/2021	160	-336	-241	-232	N/A
12/31/2020	165	-369	-261	-253	N/A
9/30/2020	161	-370	-275	-267	N/A
6/30/2020	159	-385	-279	-269	N/A
3/31/2020	152	-413	-311	-308	N/A
12/31/2019	143	-400	-343	-324	N/A
9/30/2019	134	-400	-356	-336	N/A
6/30/2019	119	-396	-376	-352	N/A
3/31/2019	110	-377	-444	-364	N/A
12/31/2018	95	-368	-430	-366	N/A
9/30/2018	82	-321	-412	-349	N/A
6/30/2018	76	-291	-380	-322	N/A
3/31/2018	67	-366	-282	-281	N/A
12/31/2017	56	-346	-265	-261	N/A
9/30/2017	39	-365	-254	-250	N/A
6/30/2017	22	-370	-268	-265	N/A
3/31/2017	7	-324	-267	-263	N/A
12/31/2016	0	-349	-267	-267	N/A
9/30/2016	N/A	-398	-290	-288	N/A
6/30/2016	N/A	-431	N/A	-299	N/A
3/31/2016	N/A	-373	N/A	-288	N/A
12/31/2015	N/A	-353	N/A	-253	N/A
9/30/2015	N/A	-288	N/A	-211	N/A
6/30/2015	N/A	-229	N/A	-174	N/A
3/31/2015	N/A	-192	N/A	-146	N/A
12/31/2014	14	-160	N/A	-117	N/A
9/30/2014	14	-134	N/A	-107	N/A
6/30/2014	14	-115	N/A	-88	N/A
3/31/2014	14	-100	N/A	-77	N/A
12/31/2013	N/A	-85	N/A	-72	N/A
9/30/2013	N/A	-76	N/A	-67	N/A
6/30/2013	N/A	-74	N/A	-65	N/A
3/31/2013	N/A	-71	N/A	-61	N/A
12/31/2012	N/A	-74	N/A	-65	N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if C6O's forecast earnings growth is above the savings rate (0.2%).

수익 vs 시장: Insufficient data to determine if C6O's earnings are forecast to grow faster than the German market

고성장 수익: Insufficient data to determine if C6O's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if C6O's revenue is forecast to grow faster than the German market.

고성장 수익: Insufficient data to determine if C6O's revenue is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if C6O's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Clovis Oncology 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue beats expectations

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €7.51

New 90-day high: €4.99

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.84

Clovis Oncology, Inc. to Report Q1, 2020 Results on May 05, 2020

Clovis Oncology, Inc. Presents Highlight Breadth and Potential of Clovis Oncology Products and Pipeline At ESMO Virtual Congress 2020

First half earnings released

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견